Pirlindole

Pirlindole

Pirlindole is a monoamine oxidase inhibitor (MAOI) that is primarily used as an antidepressant in the treatment of major depressive disorder. It is a selective and reversible inhibitor of monoamine oxidase A (MAO-A), a type of enzyme that breaks down monoamines in the body. Pirlindole was first synthesized in the 1970s and is currently marketed in several countries, including Russia and Ukraine.

Pharmacology

Pirlindole acts by inhibiting the action of monoamine oxidase A, an enzyme that is responsible for the breakdown of monoamines in the body. Monoamines include several important neurotransmitters, such as serotonin, norepinephrine, and dopamine. By inhibiting the breakdown of these neurotransmitters, pirlindole increases their levels in the brain, which can help to alleviate the symptoms of depression.

Clinical Use

Pirlindole is primarily used in the treatment of major depressive disorder. It may also be used off-label for other conditions, such as anxiety disorders and panic disorder. The typical starting dose is 150 mg per day, which may be increased to a maximum of 300 mg per day if necessary.

Side Effects

Like all medications, pirlindole can cause side effects. The most common side effects include nausea, dizziness, and insomnia. In rare cases, pirlindole can cause more serious side effects, such as hypertensive crisis or serotonin syndrome, especially when taken in combination with other medications that increase serotonin levels.

Contraindications

Pirlindole is contraindicated in individuals with a history of hypersensitivity to pirlindole or any of its components. It is also contraindicated in individuals with a history of pheochromocytoma, a rare tumor of the adrenal glands that can cause high blood pressure.

See Also

• Monoamine oxidase inhibitor
• Major depressive disorder
• Serotonin syndrome

‎